DiaMedica Therapeutics Inc DMAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DMAC is a good fit for your portfolio.
News
-
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
-
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
-
DiaMedica Therapeutics Announces $11.8 Million Private Placement
-
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
-
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
-
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
Trading Information
- Previous Close Price
- $3.69
- Day Range
- $3.61–3.74
- 52-Week Range
- $1.94–3.81
- Bid/Ask
- $3.63 / $3.64
- Market Cap
- $155.58 Mil
- Volume/Avg
- 28,008 / 61,262
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 19
- Website
- https://www.diamedica.com
Comparables
Valuation
|
Metric
|
DMAC
|
NGM
|
ATXS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.97 | 0.86 | 2.40 |
Price/Sales | — | 28.76 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
DMAC
NGM
ATXS
Financial Strength
|
Metric
|
DMAC
|
NGM
|
ATXS
|
|---|---|---|---|
Quick Ratio | 17.93 | 7.18 | 33.41 |
Current Ratio | 18.14 | 7.79 | 33.83 |
Interest Coverage | — | — | — |
Quick Ratio
DMAC
NGM
ATXS
Profitability
|
Metric
|
DMAC
|
NGM
|
ATXS
|
|---|---|---|---|
Return on Assets (Normalized) | −35.87% | −49.51% | −23.38% |
Return on Equity (Normalized) | −37.97% | −57.34% | −40.10% |
Return on Invested Capital (Normalized) | −37.64% | −61.20% | −29.23% |
Return on Assets
DMAC
NGM
ATXS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Hqgcwslqx | Llxr | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dgkhcnwdl | Gllmd | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yxnxfrj | Vwpjky | $118.7 Bil | |||
| Moderna Inc
MRNA
| Twxwshkr | Ylwt | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dpbhvdzgf | Wjkqr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Tjccnlmh | Vgl | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qcvbrmlpk | Zhbrv | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bdvtfljn | Vsyznm | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Bpmlsyx | Wbtd | $15.0 Bil | |||
| Incyte Corp
INCY
| Mpqjwyrq | Wmcfg | $13.5 Bil |